Denali Therapeutics outlines 2024 pipeline milestones, plans to spin out preclinical small molecule portfolio

Denali Therapeutics Inc.

Cash of ~$1.12B as of Sep 30, 2023; expects 2024 OpEx ≤2023, extending runway into 2027.
Plans to complete enrollment in late-stage MPS II (COMPASS) and ALS (HEALEY) trials in 2024.
DNL593 (PTV:PGRN) Phase 1/2 paused for protocol modifications after infusion-related reactions in 2 participants.
Announces spin-out of preclinical small molecule portfolio into a separately funded NewCo.
IND-enabling studies for OTV:MAPT (Alzheimer's) and OTV:SNCA (Parkinson's) expected in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.